Fig. 2
(a) Summary of clinical course of the present patient. (b) Follow-up colonoscopy images obtained at 12 (CS3), 24 (CS4), and 36 months (CS5) after diagnosis of colitis associated with dasatinib administration. CS, colonoscopy; PE, pleural effusion; DAS, dasatinib; MMR, major molecular response; defined as ≤ 0.1% (MMR), ≤ 0.01% (MR4), ≤ 0.0032% (MR4.5) BCR-ABL1 transcripts according to the international scale